MSD’s Phase II Cadence trial of Winrevair achieves primary goal

Merck plans Phase 3 Winrevair study after Phase 2 trial hits goal

Merck is planning a Phase 3 trial testing Winrevair (sotatercept-csrk) in people with combined post- and precapillary pulmonary hypertension (CpcPH) due to heart failure with preserved ejection fraction (HFpEF). CpcPH is a form of pulmonary hypertension due to left heart disease, marked by elevated blood pressure in the vessels that carry blood from the heart through the lungs and also the vessels that carry oxygen-rich blood from the lungs back…

MSD’s Phase II Cadence trial of Winrevair achieves primary goal

MSD has reported that the Phase II Cadence trial of Winrevair for CpcPH caused by HFpEF, met its primary endpoint.The post MSD’s Phase II Cadence trial of Winrevair achieves primary goal appeared first on Clinical Trials Arena.